656237-78-4

Upstream product

• 656237-77-3 N-[(1R)-1-(4-bromophenyl)ethyl]-4-chloro-3-nitropyridin-2-amine 
• 24358-62-1 (R)-1-(4-bromophenyl)ethylamine 
• 629655-23-8 2-chloro-3-nitro-4-hydroxypyridine 

Downstream Products

• 656237-79-5 4-chloro-N-2-{(1R)-1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl}pyridine-2,3-diamine 
• 676445-28-6 4-chloro-N~2~-{(1R)-1-[3'-fluoro-2'-(3-methyl-1,2,4-oxadiazol-5-yl)-1-1,1'-biphenyl-4-yl]ethyl}pyridine-2,3-diamine 
• 656237-80-8 4-chloro-N-2-{(1R)-1-[3'-fluoro-2'-(2-methyl-2H-tetrazol-5-yl)-1,1'-biphenyl-4-yl]ethyl}pyridine-2,3-diamine 

Relevant academic research and scientific papers

2,3-Diaminopyridine bradykinin B1 receptor antagonists

Bradykinin B1 receptor antagonists embody a potentially novel approach for the treatment of chronic pain and inflammation. A series of 2,3-diaminopyridine B1 antagonists was optimized to have sub-nanomolar affinity and good pharmacok

2-(Biarylalkyl)amino-3-(cyanoalkanoylamino)pyridine derivatives

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

2-(biarylalkyl)amino-3-(heterocyclylcarbonylamino)-pyridine derivatives

Compounds disclosed herein are bradykinin B1 antagonist compounds useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.